Editorial commentary: The striking prevalence of amiodarone induced hypothyroidism: an endocrinologist's perspective

Trends Cardiovasc Med. 2023 May;33(4):263-264. doi: 10.1016/j.tcm.2022.01.008. Epub 2022 Jan 31.

Authors

Fausto Bogazzi¹, Daniele Cappellani²

Affiliations

¹ Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy. Electronic address: fausto.bogazzi@med.unipi.it.
² Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Pisa, Pisa, Italy.

PMID: 35092848
DOI: 10.1016/j.tcm.2022.01.008

No abstract available

Publication types

Editorial
Comment

MeSH terms

Amiodarone* / adverse effects
Endocrinologists
Humans
Hypothyroidism* / chemically induced
Hypothyroidism* / diagnosis
Hypothyroidism* / drug therapy
Prevalence

Substances

Amiodarone